Research Field

A. Development of anti-Cancer NanoBody therapeutics and modulators for NLRP3 Inflammasome
B. We published a theory that the innate Immune System recognises the hydrophobic part (Hypo) of a substance to determine the degree of damage in the tissue, thereby providing a second signal for activation of the T lymphocytes (Nature Rev. Immunol. 2004). To tesr the model experimentally, we have studied immune responses induced by water- insoluble molecules. It was applied to the development of therapeutics for inflammatory diseases by inhibiting pathways for activation of GPCR19-P2X7R-NLRP3 inflmasome. We finished phase 2 clinical trials for atopic dermatitis and COVID-19 pneumonia in 2021. A study to control dendritic cell activation and the development of anti-cancer vaccines are underway (Nat Nanotechnol. 2011). To overcome the technological limitations of anti-cancer antibody treatments, we have developed nanobody (=15 kDa) that promote the activation of T lymphocytes, and overcome immunosuppressive environment in cancer patients.

Pure Link

Keyword

innate immunity, damage-associated molecular pattern, inflammation, atopy, pneumoniae, ulcerative colitis, NASH, single domain antibody therapeutics, cancer immunotherapy